Precision-Cut Liver Slices As an Model to Evaluate Antifibrotic Therapies for Liver Fibrosis and Cirrhosis

Overview

Journal bioRxiv

Date 2023 Nov 14

PMID 37961334

Authors

Yongtao Wang

Ben Leaker

Guoliang Qiao

Mozhdeh Sojoodi

Ibrahim Ragab Eissa

Eliana T Epstein

Jonathan Eddy

Oizoshimoshiofu Dimowo

Georg M Lauer

Raymond T Chung

Motaz Qadan

Michael Lanuti

Bryan C Fuchs

Kenneth K Tanabe

Affiliations

Soon will be listed here.

Abstract

Background: Precision-Cut Liver Slices (PCLS) are an culture model developed to study hepatic drug metabolism. One of the main benefits of this model is that it retains the structure and cellular composition of the native liver. PCLS also represents a potential model system to study liver fibrosis in a setting that more closely approximates pathology than methods. The aim of this study was to assess whether responses to antifibrotic interventions can be detected and quantified with PCLS.

Methods: PCLS of 250 μm thickness were prepared from four different murine fibrotic liver models: choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD), thioacetamide (TAA), diethylnitrosamine (DEN), and carbon tetrachloride (CCl). PCLS were treated with 5 μM Erlotinib for 72 hours. Histology and gene expression were then compared with murine experiments and TGF-β1 activated hepatic stellate cells (HSCs). These types of PCLS characterization were also evaluated in PCLS from human cirrhotic liver.

Results: PCLS viability in culture was stable for 72 hours. Treatment of erlotinib, an EGFR inhibitor significantly inhibited the expression of profibrogenic genes and in PCLS from CDAHFD-induced cirrhotic mice, and and in PCLS from TAA-induced cirrhotic rats. Erlotinib treatment of PCLS from DEN-induced cirrhotic rats inhibited the expression of and , which was consistent with the impact of erlotinib on and expression in DEN-induced cirrhosis. Erlotinib treatment of PCLS from CCl-induced cirrhosis caused reduced expression of and , which was consistent with the effect of erlotinib in CCl-induced cirrhosis. In addition, in HSCs at PCLS from normal mice, TGF-β1 treatment upregulated (), while treatment with erlotinib inhibited the expression of . Similar expression results were observed in TGF-β1 treated HSCs. Expression of MMPs and TIMPs, key regulators of fibrosis progression and regression, were also significantly altered under erlotinib treatment in PCLS. Expression changes under erlotinib treatment were also corroborated with PCLS from human cirrhosis samples.

Conclusion: The responses to antifibrotic interventions can be detected and quantified with PCLS at the gene expression level. The antifibrotic effects of erlotinib are consistent between PCLS models of murine cirrhosis and those observed and . Similar effects were also reproduced in PCLS derived from patients with cirrhosis. PCLS is an excellent model to assess antifibrotic therapies that is aligned with the principles of Replacement, Reduction and Refinement (3Rs).

References

Heindryckx F, Colle I, Van Vlierberghe H . Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol. 2009; 90(4):367-86. PMC: 2741148. DOI: 10.1111/j.1365-2613.2009.00656.x. View

. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016; 388(10053):1545-1602. PMC: 5055577. DOI: 10.1016/S0140-6736(16)31678-6. View

McGlynn K, Petrick J, London W . Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015; 19(2):223-38. PMC: 4712629. DOI: 10.1016/j.cld.2015.01.001. View

van de Bovenkamp M, Groothuis G, Draaisma A, Merema M, Bezuijen J, van Gils M . Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu. Toxicol Sci. 2005; 85(1):632-8. DOI: 10.1093/toxsci/kfi127. View

Tolba R, Kraus T, Liedtke C, Schwarz M, Weiskirchen R . Diethylnitrosamine (DEN)-induced carcinogenic liver injury in mice. Lab Anim. 2015; 49(1 Suppl):59-69. DOI: 10.1177/0023677215570086. View

de Graaf I, Olinga P, de Jager M, Merema M, de Kanter R, van de Kerkhof E . Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nat Protoc. 2010; 5(9):1540-51. DOI: 10.1038/nprot.2010.111. View

Castera L, Friedrich-Rust M, Loomba R . Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019; 156(5):1264-1281.e4. PMC: 7505052. DOI: 10.1053/j.gastro.2018.12.036. View

Schon H, Weiskirchen R . Immunomodulatory effects of transforming growth factor-β in the liver. Hepatobiliary Surg Nutr. 2015; 3(6):386-406. PMC: 4273109. DOI: 10.3978/j.issn.2304-3881.2014.11.06. View

Pearen M, Lim H, Gratte F, Fernandez-Rojo M, Nawaratna S, Gobert G . Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology. J Vis Exp. 2020; (157). DOI: 10.3791/60992. View

10.

Westra I, Oosterhuis D, Groothuis G, Olinga P . Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs. Toxicol Appl Pharmacol. 2013; 274(2):328-38. DOI: 10.1016/j.taap.2013.11.017. View

11.

Dewyse L, De Smet V, Verhulst S, Eysackers N, Kunda R, Messaoudi N . Improved Precision-Cut Liver Slice Cultures for Testing Drug-Induced Liver Fibrosis. Front Med (Lausanne). 2022; 9:862185. PMC: 9007724. DOI: 10.3389/fmed.2022.862185. View

12.

Leaker B, Wang Y, Tam J, Anderson R . Analysis of culture and RNA isolation methods for precision-cut liver slices from cirrhotic rats. Sci Rep. 2024; 14(1):15349. PMC: 11222550. DOI: 10.1038/s41598-024-66235-2. View

13.

Zhang D, Friedman S . Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology. 2012; 56(2):769-75. PMC: 4087159. DOI: 10.1002/hep.25670. View

14.

Geervliet E, Bansal R . Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases. Cells. 2020; 9(5). PMC: 7290342. DOI: 10.3390/cells9051212. View

15.

Wang H, Lafdil F, Wang L, Yin S, Feng D, Gao B . Tissue inhibitor of metalloproteinase 1 (TIMP-1) deficiency exacerbates carbon tetrachloride-induced liver injury and fibrosis in mice: involvement of hepatocyte STAT3 in TIMP-1 production. Cell Biosci. 2011; 1(1):14. PMC: 3125204. DOI: 10.1186/2045-3701-1-14. View

16.

Hubrecht R, Carter E . The 3Rs and Humane Experimental Technique: Implementing Change. Animals (Basel). 2019; 9(10). PMC: 6826930. DOI: 10.3390/ani9100754. View

17.

Huang X, Cai H, Ammar R, Zhang Y, Wang Y, Ravi K . Molecular characterization of a precision-cut rat liver slice model for the evaluation of antifibrotic compounds. Am J Physiol Gastrointest Liver Physiol. 2018; 316(1):G15-G24. PMC: 6383382. DOI: 10.1152/ajpgi.00281.2018. View

18.

Wu X, Roberto J, Knupp A, Kenerson H, Truong C, Yuen S . Precision-cut human liver slice cultures as an immunological platform. J Immunol Methods. 2018; 455:71-79. PMC: 6689534. DOI: 10.1016/j.jim.2018.01.012. View

19.

Li S, Ghoshal S, Sojoodi M, Arora G, Masia R, Erstad D . Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. J Gastrointest Surg. 2018; 23(1):101-111. PMC: 6328630. DOI: 10.1007/s11605-018-4004-6. View

20.

Yu T, Wang Y, Zhang H, Johnson C, Jiang Y, Li X . Metabolomics reveals mycoplasma contamination interferes with the metabolism of PANC-1 cells. Anal Bioanal Chem. 2016; 408(16):4267-73. PMC: 6300981. DOI: 10.1007/s00216-016-9525-9. View